List of Excipients in Branded Drug ZYPITAMAG

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medicure International Inc	ZYPITAMAG	pitavastatin magnesium	25208-201	CALCIUM CARBONATE	2031-01-19
Medicure International Inc	ZYPITAMAG	pitavastatin magnesium	25208-201	CROSPOVIDONE	2031-01-19
Medicure International Inc	ZYPITAMAG	pitavastatin magnesium	25208-201	HYPROMELLOSE	2031-01-19
Medicure International Inc	ZYPITAMAG	pitavastatin magnesium	25208-201	LACTOSE MONOHYDRATE	2031-01-19
Medicure International Inc	ZYPITAMAG	pitavastatin magnesium	25208-201	MAGNESIUM STEARATE	2031-01-19
Medicure International Inc	ZYPITAMAG	pitavastatin magnesium	25208-201	POLYETHYLENE GLYCOL	2031-01-19

ZYPITAMAG Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

ZYPITAMAG is a U.S. pitavastatin calcium tablet marketed by Zydus Pharmaceuticals. Its commercial opportunity is primarily generic and lifecycle-formulation driven rather than exclusivity driven. The current formulation uses a compact solid-dose platform built around lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium aluminometasilicate, magnesium stearate, and film-coating excipients identified in FDA labeling.[1]

The strongest opportunities are lower-cost generic supply, differentiated low-dose or orally disintegrating products, excipient substitution that improves supply resilience, and combination products targeting adherence. Patent value in the core pitavastatin molecule is limited because pitavastatin has been marketed for more than a decade and generic competition exists. Formulation patents could still protect a genuinely differentiated delivery system, but a conventional immediate-release tablet is unlikely to support broad blocking rights.

What is ZYPITAMAG and who markets it?

ZYPITAMAG contains pitavastatin calcium, an HMG-CoA reductase inhibitor used with diet to reduce low-density lipoprotein cholesterol in adults with primary hyperlipidemia or mixed dyslipidemia.[1]

Attribute	ZYPITAMAG
Active ingredient	Pitavastatin calcium
Available strengths	1 mg, 2 mg, and 4 mg tablets
Dosage form	Immediate-release, film-coated oral tablet
U.S. sponsor/marketer	Zydus Pharmaceuticals (USA) Inc.
Pharmacologic class	Statin
FDA regulatory pathway	Prescription drug approved under an NDA
Primary competitors	Generic pitavastatin, Livalo, Livazo and other regional brands
Biosimilar relevance	None; pitavastatin is a small-molecule drug
Orange Book relevance	NDA patent and exclusivity information must be verified against the current FDA Orange Book

Pitavastatin differs commercially from high-volume atorvastatin and rosuvastatin products because it has a smaller market and is often prescribed when tolerability, drug interactions, or a particular lipid-management profile influences treatment selection.

What excipients are used in ZYPITAMAG tablets?

FDA labeling identifies the principal tablet excipients as lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium aluminometasilicate, and magnesium stearate. The film coat includes hypromellose, titanium dioxide, triacetin, and colorants as applicable to the strength.[1]

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Large-volume, cost-sensitive commodity; supplier qualification is important
Low-substituted hydroxypropyl cellulose	Disintegrant and matrix-forming excipient	Supports tablet breakup and mechanical performance
Magnesium aluminometasilicate	Adsorbent, flow aid, and possible dissolution-support excipient	May influence powder flow, drug distribution, and process robustness
Magnesium stearate	Lubricant	Over-lubrication can reduce tablet tensile strength and slow dissolution
Hypromellose	Film-forming coating polymer	Enables coating uniformity and tablet protection
Titanium dioxide and iron oxides, where used	Opacifying and coloring agents	Useful for strength differentiation and product identification
Triacetin	Plasticizer in the film coat	Supports coating flexibility and reduces cracking risk

The label does not by itself establish the precise critical material attributes or the manufacturing design space. Those parameters must be assessed through formulation development, process characterization, comparative dissolution, stability testing, and regulatory filing.

How does the ZYPITAMAG excipient system support manufacturing?

The formulation is consistent with a conventional immediate-release compressed-tablet strategy. Lactose provides bulk and compressibility. Low-substituted hydroxypropyl cellulose supports disintegration while contributing to tablet structure. Magnesium aluminometasilicate can improve powder handling and may help distribute a low-dose active ingredient through the blend. Magnesium stearate provides lubrication for compression and ejection.

For the 1 mg strength, content uniformity is a central development issue because the active represents a small fraction of total tablet mass. The formulation must control:

• API particle-size distribution;
• active dilution and blend uniformity;
• segregation during transfer and compression;
• lubricant mixing time;
• tablet weight variation;
• assay and content uniformity;
• dissolution across all strengths.

The three-strength product line can reduce manufacturing complexity if the same excipient platform and compression process are used across all strengths. That approach supports common tooling, shared stability protocols, and fewer raw-material specifications.

Which excipient risks matter most?

The main technical risks are not unusual excipient toxicology concerns. They are process and performance risks.

Lactose can create supply and labeling limitations for patients who avoid lactose, although the amount in a tablet may be clinically insignificant for many patients. It also requires control of water content and solid-state characteristics.

Magnesium stearate is highly sensitive to mixing time and concentration. Excessive lubrication can weaken tablets and delay drug release. The effect is especially relevant where a generic applicant must match the reference product's dissolution profile.

Magnesium aluminometasilicate can vary by grade, particle size, surface area, and moisture content. Changes in these attributes can affect flow, compactability, and dissolution. A supplier change therefore may require more than a simple administrative assessment.

Colorants and coating systems create lower technical risk but can complicate global registration. Some markets apply different restrictions or customer preferences to titanium dioxide and certain synthetic colorants.

What commercial opportunities exist for ZYPITAMAG excipients?

Generic pitavastatin supply

The largest opportunity is supply to generic manufacturers. Pitavastatin demand is smaller than demand for atorvastatin or rosuvastatin, but generic competition creates recurring requirements for:

• lactose monohydrate;
• low-substituted hydroxypropyl cellulose;
• magnesium aluminometasilicate;
• magnesium stearate;
• hypromellose;
• film-coating premixes;
• colorant systems;
• packaging materials with moisture protection.

Excipient suppliers can compete through qualified alternate sources, lower minimum order quantities, regional inventory, and documentation packages suitable for ANDA submissions.

Excipient substitution and dual sourcing

A supplier can create value by offering a functionally equivalent alternative rather than a chemically identical product. The most practical targets are:

• alternate lactose grades with equivalent particle-size and moisture profiles;
• alternate low-substituted hydroxypropyl cellulose grades;
• replacement magnesium aluminometasilicate grades;
• directly compressible co-processed excipients;
• premixed film-coating systems;
• low-dusting lubricant blends.

The commercial barrier is comparability. The substitute must preserve blend uniformity, tablet hardness, friability, disintegration, dissolution, assay, and stability. A well-documented material-change package can reduce requalification time for generic manufacturers.

Direct-compression platforms

A co-processed excipient system could simplify production if it improves flow and compressibility without changing the release profile. This has potential value for contract manufacturers and smaller ANDA holders that lack extensive granulation infrastructure.

The best commercial positioning would focus on:

• reduced blending and granulation steps;
• improved low-dose content uniformity;
• lower tablet-weight variability;
• shorter scale-up cycles;
• reduced tooling and compression defects;
• stable performance across all three strengths.

A direct-compression platform should not be marketed as interchangeable with the ZYPITAMAG formulation unless comparative performance and regulatory acceptability are established.

What formulations could extend pitavastatin commercial value?

The core ZYPITAMAG tablet has limited differentiation. New formulations could create more defensible commercial positions.

Orally disintegrating tablets

An orally disintegrating pitavastatin tablet could target patients with swallowing difficulty, long-term polypharmacy, or adherence problems. The active dose is low, which can support a small dosage form. Development risks include taste masking, friability, moisture sensitivity, and rapid dissolution without excessive mouthfeel.

Possible excipient platforms include:

• mannitol-based diluents;
• crospovidone or croscarmellose sodium;
• porous or co-processed excipients;
• sweeteners and flavors;
• taste-masking polymers;
• moisture-barrier packaging.

An ODT may qualify for a 505(b)(2) strategy or another regulatory route depending on the formulation, labeling, and reliance on existing data. The commercial case requires evidence of a meaningful administration or adherence benefit, not only a different tablet shape.[3]

Sprinkle or dispersible products

A sprinkle formulation could address patients who cannot swallow tablets. This route creates technical challenges involving dose uniformity, palatability, food compatibility, and administration through soft food or liquids. A product that changes the administration method may support formulation and method-of-use claims if the clinical and regulatory evidence is sufficient.

Fixed-dose combinations

Pitavastatin could be evaluated in combinations with antihypertensive, antidiabetic, or triglyceride-lowering agents. Combination development would face formulation compatibility, dose-ratio, adherence, and clinical justification requirements.

Commercial attractiveness would depend on whether the combination solves a prescribing or adherence problem. A simple combination of widely generic drugs would have limited pricing power unless the product offers a clear dosing or tolerability advantage.

Pediatric and geriatric presentations

Pitavastatin labeling and clinical use are concentrated in adults. A pediatric liquid, mini-tablet, or dispersible dosage form would require age-appropriate safety, dosing, and administration data. A geriatric-focused product could use a smaller tablet, easy-open packaging, or an ODT platform. These opportunities are commercially narrower but may support specialty positioning.

What patents protect ZYPITAMAG and its formulation?

The core pitavastatin compound and early manufacturing patents are separate from later formulation rights. Because pitavastatin has long-standing global commercialization and generic versions are available, the principal commercial risk is generally not basic molecule exclusivity.

A proper patent review should distinguish four claim categories:

Claim category	Relevance to ZYPITAMAG opportunity	Expected strength
Pitavastatin compound claims	Basic active-ingredient protection	Generally limited after long commercial history
Salt or crystal-form claims	May cover pitavastatin calcium or a particular solid form	Depends on claim scope and expiration
Immediate-release tablet claims	May cover excipient ratios, particle size, or process parameters	Often vulnerable to design-around strategies
ODT, liquid, combination, or administration claims	Potential lifecycle protection	Stronger if tied to measurable clinical or technical advantages

The Orange Book should be checked for current patents and regulatory exclusivities associated with the specific ZYPITAMAG NDA.[2] Patent expiration dates should not be inferred from the reference product's approval date, because listed patents may cover different subject matter and have different patent-term adjustments, pediatric extensions, or terminal disclaimers.

Are formulation patents likely to block generic pitavastatin?

A conventional lactose-based immediate-release tablet is difficult to protect broadly. Competitors can alter:

• diluent selection;
• disintegrant type;
• lubricant concentration;
• excipient ratios;
• granulation method;
• coating composition;
• particle-size specification;
• compression force;
• tablet geometry.

A formulation patent is more defensible when it claims a narrowly defined composition linked to a measurable result, such as improved dissolution under a specified condition, enhanced stability, reduced impurity formation, or improved content uniformity at the 1 mg dose.

When does ZYPITAMAG lose exclusivity?

ZYPITAMAG's commercial exclusivity must be analyzed through three separate categories:

1. FDA regulatory exclusivity.
2. Orange Book-listed patents.
3. Market availability of AB-rated or otherwise substitutable generic pitavastatin.

FDA regulatory exclusivity is time-limited and is distinct from patent protection. The FDA Orange Book identifies listed patents, exclusivity codes, therapeutic equivalence information, and approved products.[2] Because regulatory and patent records can change, the current Orange Book entry controls the operative U.S. status.

Pitavastatin already has generic competition in the United States. That means commercial entry risk is established even if a particular ZYPITAMAG formulation or brand presentation retains limited rights. A new entrant would generally assess:

• whether an ANDA can reference the listed drug;
• whether Paragraph IV certifications are necessary;
• whether any listed patents remain enforceable;
• whether the proposed formulation avoids claimed excipient or process limitations;
• whether the product can obtain therapeutic equivalence.

Which companies are challenging or competing with ZYPITAMAG?

Competition comes from several levels:

• generic pitavastatin manufacturers;
• Livalo and other pitavastatin brands;
• high-volume statins such as atorvastatin and rosuvastatin;
• non-statin lipid-lowering products, including ezetimibe and PCSK9-directed therapies for higher-risk populations.

The most direct competitors are generic pitavastatin suppliers. Their commercial advantage is price and payer substitution. ZYPITAMAG can compete through supply reliability, contracting, authorized distribution, strength availability, and prescriber familiarity.

Large statin brands have greater scale and formulary access. Pitavastatin's opportunity is narrower and depends on patient selection rather than broad population volume.

What is the FDA and Orange Book status of ZYPITAMAG?

ZYPITAMAG is an FDA-approved prescription tablet. Its regulatory profile is that of a small-molecule oral drug, not a biologic, so biosimilar pathways do not apply.[1,2]

The relevant U.S. regulatory questions are:

• whether ZYPITAMAG is listed as a reference product or as a separate branded NDA;
• whether pitavastatin ANDAs have therapeutic-equivalence ratings;
• which patents, if any, are listed against the applicable NDA;
• whether any exclusivity remains active;
• whether a new formulation would use an ANDA, 505(b)(2), or another pathway.

An excipient change to a generic product can often be managed through an ANDA supplement if the product remains within the approved quality and performance framework. A new dosage form, new route, or clinically distinct administration method may require a more substantial filing strategy.[3]

What generic launch risks exist for ZYPITAMAG?

Low-risk launch scenario

A manufacturer launches a conventional immediate-release pitavastatin tablet using a non-infringing excipient system, demonstrates bioequivalence, and obtains an acceptable therapeutic-equivalence rating. Price competition is the principal risk to the branded product.

Moderate-risk launch scenario

A manufacturer uses the same general excipient classes but changes grades, ratios, or manufacturing process. The main risks are dissolution mismatch, content-uniformity failure at 1 mg, stability differences, and regulatory questions regarding formulation comparability.

Higher-value differentiated launch

A manufacturer introduces an ODT, sprinkle, mini-tablet, or fixed-dose combination. The product may avoid direct tablet-to-tablet competition but requires additional development, clinical justification, patent work, and commercial education.

How strong is the ZYPITAMAG patent estate?

The patent estate is likely moderate to weak for broad commercial blocking purposes and stronger only for narrowly defined formulation or process claims. The molecule is mature, generic pitavastatin is available, and an immediate-release tablet can be designed around using alternative excipients.

The most promising IP strategy is a layered lifecycle estate covering:

• a defined solid form or particle-size distribution;
• impurity control during manufacture and storage;
• a stable low-dose composition;
• rapid disintegration with demonstrated dissolution performance;
• ODT or sprinkle administration;
• a clinically supported combination product;
• packaging and moisture-control systems where the claims are technically specific.

Commercial value would increase if the formulation patents were paired with a distinct FDA label and a reimbursed administration or adherence benefit.

What licensing and partnership opportunities exist?

Publicly disclosed deal data specifically tied to the ZYPITAMAG excipient platform is limited. The practical partnership opportunities are broader than licensing the current tablet composition.

Potential counterparties include:

• excipient manufacturers seeking a qualified pitavastatin platform;
• contract development and manufacturing organizations;
• generic companies seeking alternate-source qualification;
• specialty pharmaceutical companies developing adherence products;
• regional distributors in markets where pitavastatin remains branded;
• packaging suppliers offering high-barrier systems.

The most licensable assets would be a validated ODT or sprinkle platform, a co-processed low-dose direct-compression system, or a stability package that reduces manufacturing and regulatory risk across multiple pitavastatin strengths.

What is the revenue exposure for ZYPITAMAG?

ZYPITAMAG revenue is not generally reported as a separately disclosed line item by its marketer. Exposure should therefore be modeled using prescription volume, net price, payer mix, gross-to-net deductions, and the share of pitavastatin prescriptions captured by the brand.

The revenue risk is asymmetric:

• generic entry creates rapid price and volume pressure;
• excipient substitution can reduce cost of goods;
• a differentiated formulation could expand the addressable patient segment;
• a conventional excipient improvement alone is unlikely to support a material price premium.

For excipient suppliers, the opportunity is recurring but volume constrained. For drug developers, the value lies in lifecycle products rather than the existing tablet architecture.

Key Takeaways

• ZYPITAMAG is a pitavastatin calcium immediate-release tablet marketed by Zydus Pharmaceuticals.
• Its labeled excipient system uses lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium aluminometasilicate, magnesium stearate, and film-coating materials.
• The strongest near-term excipient opportunity is qualified alternate sourcing and cost reduction for generic pitavastatin manufacturers.
• Low-dose content uniformity, magnesium stearate lubrication, powder flow, and dissolution are the principal technical controls.
• Broad patent protection for a conventional immediate-release tablet is difficult to sustain against design-around formulations.
• ODT, sprinkle, mini-tablet, and fixed-dose combination products offer more substantial lifecycle opportunities.
• ZYPITAMAG has no biosimilar issue because pitavastatin is a small molecule.
• Current Orange Book patents and exclusivity codes must control any final U.S. launch or litigation assessment.
• Public product-level revenue and ZYPITAMAG-specific licensing data are not generally disclosed.

FAQs

Can lactose-free excipients improve the commercial positioning of pitavastatin?

Yes. A lactose-free formulation could address manufacturing preferences and patient-labeling concerns, but it would need to demonstrate equivalent performance and a meaningful market advantage. Lactose removal alone is unlikely to support strong pricing power.

Is magnesium aluminometasilicate essential to a generic pitavastatin tablet?

No. A generic manufacturer may use another excipient or process if the resulting product meets quality, dissolution, bioequivalence, and regulatory requirements. The formulation change could still require extensive development and documentation.

Could a pitavastatin ODT receive new patent protection?

Yes. An ODT could support composition, taste-masking, disintegration, stability, and administration claims. Patent strength would depend on claim specificity, technical results, and the prior-art record.

Does a new excipient create a new FDA exclusivity period?

Usually not by itself. A new excipient or excipient combination may support a new product or regulatory filing, but FDA exclusivity depends on the statutory pathway and the nature of the innovation, not simply on changing inactive ingredients.

Are excipient suppliers exposed to Paragraph IV litigation?

Potentially. Paragraph IV litigation usually concerns patents listed for the drug product, but an ANDA applicant may face infringement allegations involving formulation, process, solid-form, or method-of-use claims. Excipient suppliers can become involved through indemnity provisions, technical discovery, or supply agreements.

References

1. U.S. Food and Drug Administration. (n.d.). Zypitamag (pitavastatin calcium) tablets prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2022). 505(b)(2) applications. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2015). ANDAs for certain highly variable drugs. Center for Drug Evaluation and Research.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary..core иттипақ